Press release - 30/03/2022 CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV CureVac N.V. a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that the first participant was dosed in a Phase 1 study of COVID-19 second-generation mRNA vaccine candidate, CV2CoV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-and-gsk-start-clinical-development-second-generation-covid-19-vaccine-candidate-cv2cov
Press release - 29/03/2022 Biocopy presents "ValidaTe" – A novel ultra-fast screening technology ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology
Press release - 21/03/2022 BMBF funds Heidelberg Junior Research Group for 3D Bioprinting Project Junior Professor Dr Daniela Duarte Campos has been awarded a substantial grant from the Federal Ministry of Education and Research (BMBF). She and her junior research group are investigating bioprinting for tissue and organ engineering at the Center for Molecular Biology of Heidelberg University and at the “3D Matter Made to Order” Cluster of Excellence, a collaboration between Ruperto Carola and Karlsruhe Institute of Technology (KIT).https://www.gesundheitsindustrie-bw.de/en/article/press-release/bmbf-funds-heidelberg-junior-research-group-3d-bioprinting-project
Press release - 18/03/2022 Less fossil oil in CO2-reducing plastics The "carbonauten minus CO2 factory 1" will start production of 4,000 t of CO2-reducing plastic granules annually at favorable prices in summer 2022.https://www.biooekonomie-bw.de/en/articles/pm/weniger-erdoel-co2-senkenden-kunststoffen
Press release - 18/03/2022 Lung Tissue from the Lab Laboratory studies of lung tissue usually require the removal of large amounts of human or animal tissue. Now scientists from the University of Freiburg’s Faculty of Medicine have succeeded in collaboration with American researchers in generating tiny quantities of lung tissue, so-called organoids, from just a few body cells in the lab.https://www.gesundheitsindustrie-bw.de/en/article/press-release/lung-tissue-lab
Event - 14/12/2022 - 15/12/2022 Meet & Match Cell and Gene Therapy Online, Meet & Match https://www.bio-pro.de/en/events/meet-match-cell-and-gene-therapy
Event - 19/05/2022 Lunch & Learn Market Access and Opportunities for Medtech Companies in the United Kingdom and Germany Online, Information event https://www.bio-pro.de/en/events/lunch-learn-market-access-and-opportunities-medtech-companies-united-kingdom-and-germany
Lentil cultivation and cleaning on the farm - EIP-AGRI Rhizo-Linse project - 16/03/2022 Lentils return to the Heckengäu region Lentils are among the oldest crop plants in Central European agriculture and were once a popular food in ancient Egypt, Persia and Mesopotamia. The legume was widespread in Germany until the mid-20th century, but has since disappeared completely from farmers’ fields. Over the past decade, lentils have reappeared as a crop grown locally and are cultivated in harmony with nature.https://www.biooekonomie-bw.de/en/articles/news/lentils-return-heckengaeu-region
SolidCAR-T project - 15/03/2022 Modular ‘mini-factories’ for decentralised production of CAR T cells Novel CAR T-cell therapies have proved to be promising therapeutic options for the treatment of acute leukaemias and lymphomas. Researchers from the Fraunhofer IPA in Stuttgart, the University Hospital Tübingen and the NMI in Reutlingen have joined forces in the SolidCAR-T project that aims to generate CAR T cells to combat solid tumours and produce these cells directly on site in the clinic using automated 'mini-factories'.https://www.gesundheitsindustrie-bw.de/en/article/news/modular-mini-factories-decentralised-production-car-t-cells
Press release - 14/03/2022 Do gut bacteria influence treatment success of CAR-T cell therapies? Through the Endeavour Awards, the Mark Foundation supports research projects that bring together scientists from different disciplines to advance the prevention, diagnosis and treatment of cancer. One of the only four Endeavour Awards presented this year goes to a project coordinated by scientists from the German Cancer Research Center (DKFZ).https://www.gesundheitsindustrie-bw.de/en/article/press-release/do-gut-bacteria-influence-treatment-success-car-t-cell-therapies
Press release - 10/03/2022 Innovation Day Upper Rhine provides cross-border knowledge transfer Inspiration, innovation, networking are the name of the game on April 12, 2022, when the trinational event “Innovation Day Upper Rhine” (IDUR) takes place at the Palais Universitaire on the University of Strasbourg campus. Twelve universities in the Upper Rhine region, including the University of Freiburg and 100 partner companies of the EU funded project “Knowledge Transfer Upper Rhine” (KTUR), invite to a day of exchange and meeting.https://www.gesundheitsindustrie-bw.de/en/article/press-release/innovation-day-upper-rhine-provides-cross-border-knowledge-transfer
Alternative foodstuff ? - 09/03/2022 Hemp: regional superfood and valuable source of protein If there were a competition for the ‘crop of the future’, hemp would certainly be at the top. But not because of the intoxicating effect of some hemp varieties. Cannabis has the potential to help supply protein in the quantities required by a growing world population – in a sustainable way. The TASTINO project brings together researchers from academia and industry to work on ways to make the regional superfood available as a vegan alternative.https://www.biooekonomie-bw.de/en/articles/news/hemp-regional-superfood-and-valuable-source-protein
Press release - 03/03/2022 Identifying Alzheimer's risks – as early as 17 years before diagnosis In order to develop approaches for the prevention and treatment of Alzheimer's dementia in clinical trials, it would be helpful to be able to identify people with a particularly high risk of developing the disease. But which biomarkers can indicate an increased likelihood of disease early on in symptom-free people who actually develop Alzheimer's later?https://www.gesundheitsindustrie-bw.de/en/article/press-release/identifying-alzheimers-risks-early-17-years-diagnosis
Elastin as artificial muscle material - 02/03/2022 Artificial muscle from proteins for diverse future applications As far as diversity and complexity are concerned, proteins are nature's smallest marvels. Biotechnologists have already used natural proteins as a basis for the development, bespoke design and production of artificial systems. This is what the livMatS cluster of excellence at the University of Freiburg has been doing. Researchers in the cluster have successfully produced an artificial muscle from elastin that functions autonomously.https://www.gesundheitsindustrie-bw.de/en/article/news/artificial-muscle-proteins-diverse-future-applications
Press release - 02/03/2022 Biorefinery project KoalAplan is extracting raw materials from wastewater The Ministry of the Environment, Climate Protection and the Energy Sector is funding the KoalAplan project, which extends the functional scope of a wastewater treatment plant. The project, based in the Stuttgart district of Büsnau, aims at recovering raw materials from wastewater and is therefore making a positive contribution to climate neutrality, as the products obtained replace fossil raw materials and energy-intensive processes.https://www.biooekonomie-bw.de/en/articles/pm/biorefinery-project-koalaplan-extracting-raw-materials-wastewater
Press release - 02/03/2022 HPV vaccination: Numerous studies provide impressive proof of effectiveness against cervical cancer More and more data from various European countries prove: Vaccination against human papillomavirus not only prevents precancerous lesions, but also reliably protects against cervical cancer. On the occasion of the International HPV Awareness Day on March 4, Nobel laureate Harald zur Hausen hopes that many more parents will recognize this unique opportunity to protect their children from preventable cancers by vaccinating against HPV.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hpv-vaccination-numerous-studies-provide-impressive-proof-effectiveness-against-cervical-cancer
Press release - 02/03/2022 Pilot project RoKKa uses wastewater to produce fertiliser and raw materials The Ministry for the Environment, Climate Protection and the Energy Sector is funding the new research project RoKKa which is used to prove the viability of recovering raw materials from wastewater. This adds a crucial function to the scope of a conventional sewage treatment plant. Together with the operators of the sewage treatment plants in Erbach and Neu-Ulm, the project partners demonstrate the positive contribution towards climate protection…https://www.biooekonomie-bw.de/en/articles/pm/die-klaeranlage-der-zukunft-heisst-bioraffinerie
Press release - 01/03/2022 CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer® The RNA Printer® is CureVac’s integrated and automated manufacturing solution for RNA vaccines and therapeutics. CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer®. Dr. Markus Bergmann appointed as General Manager for CureVac RNA Printer GmbH.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-gruendet-tochtergesellschaft-zur-weiterentwicklung-des-rna-printer
Press release - 22/02/2022 Better understanding communication between neurons in the brain In the field of optogenetics, scientists investigate the activity of neurons in the brain using light. A team led by Prof. Dr. Ilka Diester and Dr. David Eriksson from the Optophysiology Laboratory at the University of Freiburg has developed a new method to simultaneously conduct laminar recordings, multifiber stimulations, 3D optogenetic stimulation, connectivity inference, and behavioral quantification on brains.https://www.gesundheitsindustrie-bw.de/en/article/press-release/better-understanding-communication-between-neurons-brain
Macrophages interacting with cytomegaloviruses - 22/02/2022 Cytomegaloviruses subvert macrophage identity Cytomegaloviruses are basically harmless. However, if they occur along with other pathogens, they can trigger serious diseases. They can manipulate our immune system and encourage resident defence cells to migrate. Researchers at the Centre for Chronic Immunodeficiency (CCI) at the Freiburg University Medical Centre have discovered which mechanisms underlie the behavioural changes in macrophages that make it easier for other pathogens to attack.https://www.gesundheitsindustrie-bw.de/en/article/news/cytomegaloviruses-subvert-macrophage-identity
Natural fibers in use - 15/02/2022 Sustainable reinforcement of e-bike battery cases Ansmann AG from Assamstadt provides mobile energy solutions with a focus on sustainability. The BioBattery project, which was awarded the Baden-Württemberg Bioeconomy Innovation Prize, saw Ansmann AG working with the Fraunhofer LBF in Darmstadt to develop a natural fibre reinforced plastic composite for use in e-bike battery cases.https://www.biooekonomie-bw.de/en/articles/news/sustainable-reinforcement-e-bike-battery-cases
Press release - 10/02/2022 CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate, CVSQIV, developed in collaboration with GSK.https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-doses-first-participant-phase-1-study-multivalent-influenza-vaccine-candidate-based-second-generation-mrna-backbone-deve
Press release - 09/02/2022 Connecting fibres: The cellulose fibre industry impresses with innovation and vision The annual highlight of the industry is the International Conference on Cellulose Fibres in Cologne (www.cellulose-fibres.eu), where the latest innovations were showcased last week: new cellulose fibre technologies for various feedstocks and a wide range of hygiene and textile products as well as alternatives to plastics and carbon fibre for lightweight constructions.https://www.biooekonomie-bw.de/en/articles/pm/connecting-fibres-cellulose-fibre-industry-impresses-innovation-and-vision
Press release - 08/02/2022 New European Research Council grant for Max Plack Researcher The European Research Council is funding a large-scale proof-of-concept study on a new genome sequencing method called “Haplotagging”. Haplotagging is a new method for sequencing our genome with superior quality and faster speed, developed by group leader Frank Chan and his team at the Friedrich Miescher Laboratory at the Max Planck Campus, Tübingen, Germany.https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-european-research-council-grant-max-plack-researcher
Press release - 03/02/2022 The 5G-OR Project is a Winner of the joint Franco-German Program for the Development of innovative Applications for 5G private Networks 5G-OR is one of the 4 winning projects jointly selected by the Federal Ministry of Economics and Climate Action in Germany and the Ministry of Economy, Finance and Relaunch in France for the call “Technical developments and application ecosystems for 5G private networks”. The joint Franco-German 5G-OR project takes up the challenge in the healthcare domain.https://www.gesundheitsindustrie-bw.de/en/article/press-release/5g-or-project-winner-joint-franco-german-program-development-innovative-applications-5g-private-networks